# TScan Therapeutics, Inc.: overview TCRX · Nasdaq · CIK 1783328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tcrx.md) · [Financials](/companies/tcrx/financials.md) · [Filings](/companies/tcrx/filings.md) · [Insiders](/companies/tcrx/insiders.md) Latest reported revenue: [$1.1m](/filings/0001193125-26-345749.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-345749). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.0](/filings/0001193125-25-275933.md) | [0.7 d](/filings/0001193125-26-089884.md) | [2.2](/filings/0001193125-26-207572.md) | [3.1](/filings/0001193125-26-345749.md) | [2.5](/filings/0001193125-25-275933.md) | [2.6 d](/filings/0001193125-26-089884.md) | [1.0](/filings/0001193125-26-207572.md) | [1.1](/filings/0001193125-26-345749.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(3109.8%)](/filings/0001193125-25-275933.md) | [(5520.6%) d](/filings/0001193125-26-089884.md) | [(1669.7%)](/filings/0001193125-26-207572.md) | [(1256.6%)](/filings/0001193125-26-345749.md) | [(1475.6%)](/filings/0001193125-25-275933.md) | [(929.4%) d](/filings/0001193125-26-089884.md) | [(2967.3%)](/filings/0001193125-26-207572.md) | [(2901.3%)](/filings/0001193125-26-345749.md) | | Net margin | % | [(2849.1%)](/filings/0001193125-25-275933.md) | [(5384.8%) d](/filings/0001193125-26-089884.md) | [(1571.9%)](/filings/0001193125-26-207572.md) | [(1201.3%)](/filings/0001193125-26-345749.md) | [(1422.1%)](/filings/0001193125-25-275933.md) | [(895.1%) d](/filings/0001193125-26-089884.md) | [(2919.1%)](/filings/0001193125-26-207572.md) | [(2888.6%)](/filings/0001193125-26-345749.md) | | Diluted EPS | $ per share | [(0.25)](/filings/0001193125-25-275933.md) | not reported | [(0.26)](/filings/0001193125-26-207572.md) | [(0.28)](/filings/0001193125-26-345749.md) | [(0.28)](/filings/0001193125-25-275933.md) | not reported | [(0.22)](/filings/0001193125-26-207572.md) | [(0.23)](/filings/0001193125-26-345749.md) | | Free cash flow | $m | [(29.3) d](/filings/0001193125-25-275933.md) | [(28.3) d](/filings/0001193125-26-089884.md) | [(39.1)](/filings/0001193125-26-207572.md) | [(34.5) d](/filings/0001193125-26-345749.md) | [(33.9) d](/filings/0001193125-25-275933.md) | [(32.2) d](/filings/0001193125-26-089884.md) | [(24.3)](/filings/0001193125-26-207572.md) | [(28.0) d](/filings/0001193125-26-345749.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.1](/filings/0000950170-23-006589.md) | [13.5](/filings/0000950170-24-026875.md) | [21.0](/filings/0000950170-25-033077.md) | [2.8](/filings/0001193125-26-089884.md) | [10.3](/filings/0001193125-26-089884.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(479.6%)](/filings/0000950170-23-006589.md) | [(492.3%)](/filings/0000950170-24-026875.md) | [(444.0%)](/filings/0000950170-25-033077.md) | [(4787.7%)](/filings/0001193125-26-089884.md) | [(1315.4%)](/filings/0001193125-26-089884.md) | | Net margin | % | [(479.5%)](/filings/0000950170-23-006589.md) | [(489.3%)](/filings/0000950170-24-026875.md) | [(423.9%)](/filings/0000950170-25-033077.md) | [(4527.7%)](/filings/0001193125-26-089884.md) | [(1256.8%)](/filings/0001193125-26-089884.md) | | Diluted EPS | $ per share | [(4.17)](/filings/0000950170-23-006589.md) | [(2.75)](/filings/0000950170-24-026875.md) | [(1.36)](/filings/0000950170-25-033077.md) | [(1.14)](/filings/0001193125-26-089884.md) | [(1.00)](/filings/0001193125-26-089884.md) | | Free cash flow | $m | [(58.6)](/filings/0000950170-23-006589.md) | [(70.7)](/filings/0000950170-24-026875.md) | [(64.5)](/filings/0000950170-25-033077.md) | [(115)](/filings/0001193125-26-089884.md) | [(140)](/filings/0001193125-26-089884.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tcrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $7.9m | 8,019,148 | | Unchanged | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $5.5m | 5,564,290 | | Unchanged | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $2.7m | 2,784,792 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.1m | 2,158,831 | | Added +4,575 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.9m | 1,949,604 | | Added +740,595 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.3m | 1,326,799 | | Reduced −37,984 | | [Deer Management Co. LLC](/funds/1494127.md) | 2026-06-30 | $1.2m | 1,245,504 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.1m | 1,163,611 | | Reduced −296,674 | | [JACOBS LEVY EQUITY MANAGEMENT, INC](/funds/884414.md) | 2026-06-30 | $1.0m | 1,049,806 | | Added +241,450 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $989.0k | 1,009,107 | | Added +690,696 | ## Recent filings [All 330 filings](/companies/tcrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:07 ET | [DEF 14A](/filings/0001193125-26-431045.md) | Proxy statement, period 2026-11-20 | 0001193125-26-431045 | | 2026-10-16 | 16:45 ET | [8-K](/filings/0001193125-26-424198.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-424198 | | 2026-09-30 | 17:00 ET | [8-K](/filings/0001193125-26-409199.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-409199 | | 2026-09-11 | 08:00 ET | [8-K](/filings/0001193125-26-388631.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-388631 | | 2026-09-02 | 07:22 ET | [8-K](/filings/0001193125-26-379343.md) | 2.05 Exit or disposal costs; 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-379343 | | 2026-08-18 | 17:00 ET | [8-K](/filings/0001193125-26-355664.md) | 1.02 Termination of a material agreement | 0001193125-26-355664 | | 2026-08-12 | 07:30 ET | [10-Q](/filings/0001193125-26-345749.md) | Quarterly report, period 2026-06-30 | 0001193125-26-345749 | | 2026-08-12 | 07:15 ET | [8-K](/filings/0001193125-26-345732.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-345732 | | 2026-06-22 | 07:09 ET | [8-K](/filings/0001193125-26-276693.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-276693 | | 2026-05-22 | 16:05 ET | [8-K](/filings/0001193125-26-236862.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-236862 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-089884.md), filed Mar 4, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d2329538-47fe-4952-9c34-c8de19a56029) ## About the filer - CIK: 1783328 - Tickers: TCRX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 08:08 ET. No prices; not investment advice.